Michael Kinch

Michael Kinch currently serves as the Chief Innovation Officer at Stony Brook University and has been an Academic Affiliate at Analysis Group since November 2020. Previously, Michael was the Acting Chief Executive Officer of Resonance Pharmaceuticals, where the focus was on innovative solutions for diagnosing severe diseases. As the Executive Dean of Science and Vice President for Innovation at Long Island University, Michael led initiatives to develop programs for future scientists and medical professionals. In addition to authorship of two notable books on vaccines and cancer immunology, Michael has provided advisory services at Lewis & Clark Ventures and has held significant roles at Washington University in St. Louis, including restructuring innovation infrastructures. Education includes a PhD in Microbiology and Immunology from Duke University and a Bachelor of Science in Molecular Genetics from The Ohio State University.